メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
富山大学 ホーム
日本語
English
ホーム
プロファイル
研究部門
プロジェクト
研究成果
データセット
受賞
活動
コース
専門知識、名前、または所属機関で検索
内科学（第三）講座
富山大学
医学系
概要
フィンガープリント
ネットワーク
プロファイル
(8)
プロジェクト
(8)
研究成果
(451)
データセット
(22)
フィンガープリント
内科学（第三）講座が活動している研究トピックを掘り下げます。これらのトピックラベルは、この組織のメンバーの研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Keyphrases
Lenvatinib
48%
Hepatocellular Carcinoma
45%
Japan
45%
Crohn's Disease
41%
Unresectable Hepatocellular Carcinoma
41%
Ulcerative Colitis
41%
Endoscopic Ultrasound-guided Fine-needle Aspiration (EUS-FNA)
40%
Confidence Interval
32%
Atezolizumab Plus Bevacizumab
29%
Adverse Events
27%
Inflammatory Bowel Disease
27%
Tumor
24%
Hepatocellular Carcinoma Patients
22%
Malignant Biliary Obstruction
21%
Overall Survival
21%
Endoscopic Papillary Large Balloon Dilatation (EPLBD)
21%
Endoscopic Ultrasound-guided
20%
Chemotherapy
19%
Liver
19%
Advanced Gastric Cancer
18%
Common Bile Duct Stones
18%
Endoscopic Sphincterotomy
17%
Hazard Ratio
17%
Multivariate Analysis
16%
Progression-free Survival
15%
Helicobacter Pylori (H. pylori)
15%
Advanced Hepatocellular Carcinoma
15%
Endoscopic Ultrasonography
15%
Pancreatitis
15%
Japanese Patients
15%
Recurrent Biliary Obstruction
15%
Odds Ratio
14%
Gastric Cancer
14%
Endoscopic Surgery
14%
Endoscopic Retrograde Cholangiopancreatography
13%
Endoscopic Ultrasound
13%
Gemcitabine
12%
Albumin-bilirubin Grade
12%
Sorafenib
12%
Stent
12%
Risk Factors
12%
Benign Biliary Stricture
12%
Pancreatic Cancer
11%
Bile Duct Stones
11%
Walled-off
11%
Prospective Randomized Trial
11%
Cisplatin
11%
Clinical Outcomes
11%
Multicenter Cohort Study
10%
Pathological Diagnosis
10%
Multicenter Retrospective Study
10%
Methylation Status
10%
Endoscopic Management
10%
Diffuse Large B-cell Lymphoma (DLBCL)
10%
Radiofrequency Ablation
10%
Stricture
10%
Older Women
10%
Ultrasonographic Guidance
10%
Nonalcoholic Steatohepatitis
9%
Liver Disease
9%
Colonoscopy
9%
Biliary Stenting
9%
Gastric mucosa
9%
Phase II Study
9%
Older Men
9%
Predictive Factors
9%
Biopsy Specimen
9%
Randomized Controlled Trial
9%
Bevacizumab
9%
Prospective pilot Study
8%
Methylation
8%
Multicenter Randomized Controlled Trial
8%
Hepatic Function
8%
Endoscopic Diagnosis
8%
Adalimumab
8%
Double-balloon Enteroscopy
8%
Endoscopic Ultrasound-guided Biliary Drainage (EUS-BD)
8%
EUS-guided
8%
Monoclonal Antibody
8%
Bleeding
8%
Prognostic Factors
8%
Small Intestine
8%
Stent Placement
8%
No Significant Difference
8%
Median Progression-free Survival
8%
Clinical Features
8%
Combination Therapy
8%
Acyclic Retinoid
8%
Pancreatic Cancer Cells
8%
Plastic Stent
8%
Meta-analysis
8%
Consecutive Patients
8%
Gastrointestinal Stromal Tumor
8%
DNA Methylation (DNAm)
8%
Helicobacter Pylori Infection
8%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
7%
Hepatitis B Virus
7%
Covered Self-expandable Metallic Stent
7%
Necrosis
7%
Guidewire
7%
Medicine and Dentistry
Hepatocellular Carcinoma
84%
Endoscopic Ultrasound
63%
Cholestasis
48%
Lenvatinib
43%
Neoplasm
39%
Adverse Event
38%
Endoscopic Ultrasound Guided Fine Needle Biopsy
37%
Balloon Dilatation
26%
Ulcerative Colitis
26%
Disease
25%
Diagnosis
24%
Overall Survival
24%
Bevacizumab
22%
Crohn's Disease
22%
Atezolizumab
21%
Biopsy Technique
21%
Abdominal Cancer
21%
Common Bile Duct Stone
21%
Stenting
19%
Endoscopic Retrograde Cholangiopancreatography
19%
Chemotherapy
19%
Patient with Ulcerative Colitis
18%
Pancreatitis
18%
Endoscopic Sphincterotomy
17%
Fine-Needle Aspiration
17%
Pancreas Cancer
16%
Randomized Controlled Trial
16%
Self-Expandable Metallic Stent
16%
Inflammatory Bowel Disease
15%
Patient with Crohn's Disease
15%
Progression Free Survival
15%
Biliary Tract Drainage
14%
Lymphocyte
14%
Hazard Ratio
14%
Pancreatic Duct
13%
Endoscopy
13%
Colonoscopy
13%
Radiofrequency Ablation
12%
Stricture
12%
Nonalcoholic Fatty Liver
12%
Bile Duct Stone
12%
Retrospective Study
12%
Multivariate Analysis
12%
Liver Function
11%
Computer Assisted Tomography
11%
Bleeding
11%
Malignant Neoplasm
11%
Recurrent Disease
11%
Cancer
11%
Odds Ratio
10%
Bilirubin
10%
Clinical Trial
10%
Necrosis
10%
Surgery
10%
Patient with Inflammatory Bowel Disease
9%
Stent Placement
9%
Cholangiocarcinoma
9%
Magnetic Resonance Imaging
9%
Ulcer
9%
Bile Duct
9%
Infection
8%
Liver Cirrhosis
8%
Capsule Endoscopy
8%
Cohort Analysis
8%
Cannulation
8%
Prospective Study
8%
Liver Disease
8%
Predictive Factor
8%
Sclerosing Cholangitis
8%
Neutrophil
7%
Prognostic Factor
7%
Immunoglobulin G4
7%
Stenosis
7%
Arm
7%
Diagnostic Accuracy
7%
Biliary Tract Endoscopy
7%
Helicobacter Pylori
7%
Clinical Feature
7%
Celiac Plexus Neurolysis
7%
Double-Balloon Enteroscopy
6%
Sorafenib
6%
Endoscopic Submucosal Dissection
6%
Chronic Pancreatitis
6%
Differential Diagnosis
6%
Extracorporeal Shock Wave Lithotripsy
6%
Placebo
6%
Hepatitis B Virus
6%
Quality of Life
6%
Lithotripsy
6%
Echography
6%
N [bis(1 Aziridinyl)phosphinyl] 4 Iodobenzamide
6%
Liver Cancer
6%
Histology
6%
Ascites
6%
Diffuse Large B-Cell Lymphoma
6%
Retrospective Cohort Study
6%
Acute Pancreatitis
6%
Combination Therapy
6%
Meta-Analysis
5%
Cholangitis
5%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Lenvatinib
46%
Bevacizumab
37%
Atezolizumab
36%
Overall Survival
35%
Adverse Event
32%
Abdominal Cancer
29%
Chemotherapy
27%
Crohn's Disease
26%
Ulcerative Colitis
25%
Progression Free Survival
24%
Disease
22%
Neoplasm
21%
Pancreas Cancer
18%
Combination Therapy
16%
Inflammatory Bowel Disease
16%
Remission
15%
Bilirubin
14%
Malignant Neoplasm
14%
Sorafenib
13%
Gemcitabine
12%
Retrospective Study
11%
Nonalcoholic Fatty Liver
11%
Helicobacter Pylori
10%
Cisplatin
10%
Diffuse Large B Cell Lymphoma
10%
Retinoid
10%
Clinical Trial
9%
Tumor Necrosis Factor
8%
Liver Disease
8%
Epidermal Growth Factor Receptor
8%
Monotherapy
8%
Biological Marker
8%
Liver Injury
8%
Placebo
7%
Liver Cancer
7%
Colon Carcinoma
7%
Adalimumab
7%
Injury
7%
Ulcer
6%
Normal Human
6%
Prospective Study
6%
Survival Rate
6%
Biliary Tract Cancer
6%
Rituximab
6%
Hepatitis B Virus
6%
Liver Cirrhosis
6%
Infection
6%
Pancreatitis
6%
Fluoropyrimidine
6%
Common Bile Duct Stone
5%
Liver Fibrosis
5%
Fluorouracil
5%
Ascites
5%
Recurrent Disease
5%
Mercaptopurine
5%
Infliximab
5%
Ramucirumab
5%
Fetoprotein
5%
Hepatitis C Virus
5%
Irinotecan
5%
Messenger RNA
5%
Doxorubicin
5%
Non-Steroidal Anti-Inflammatory Drug
5%
Gastric Mucosa
5%
Disease Activity
5%
Randomized Controlled Trial
5%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
5%